In Asia, EC is the sixth most common cancer, with the region constituting almost 80% of the new EC cases globally. The highest standardized incidence rate has been observed in East Asia.
Novotech Publishes Multi-Specific Monoclonal Antibodies Global Clinical Trial Landscape Report
Singapore - Novotech, the leading Asia Pacific centred biotech CRO has published
Read more